Welcome to our dedicated page for Century Therapeutics SEC filings (Ticker: IPSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Century Therapeutics, Inc. filings document a biotechnology issuer developing iPSC-derived cell therapy programs for autoimmune diseases and cancer, along with the formal records supporting its public-company governance and capital structure. Form 8-K reports include operating and financial results, Regulation FD investor-presentation materials, clinical and regulatory program disclosures, and board composition changes.
Proxy and shareholder-vote materials cover annual meeting matters, board and committee governance, and charter-amendment voting, including reverse-stock-split authority. Capital-structure filings include shelf registration and at-the-market equity offering disclosures for common stock, while cover-page disclosures identify Century as an emerging growth company.
IPSC registers the resale of up to 176,086,947 shares of common stock for resale or other disposition by the selling stockholders named in the prospectus supplement.
This supplement substitutes SILV Fund, Ltd. for Point72 Associates, LLC in the selling stockholders table and updates that holder's row to reflect a prior ownership of 7,057,359 shares and a maximum of 3,260,869 shares to be sold under the prospectus. Shares outstanding were 180,102,343 as of March 31, 2026.
Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger had 31,172 shares of Common Stock withheld by the company to cover taxes tied to restricted stock units vesting. After this tax-withholding disposition, he holds 3,679,786 shares of Century Therapeutics Common Stock directly.
Century Therapeutics, Inc. ownership update: Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen report shared voting and dispositive power over 5,964,678 shares of common stock, equal to 3.3% of the class as of March 31, 2026. The filing states these Reporting Persons hold no shares directly and that Point72 Asset Management maintains investment and voting power for an investment fund it manages; Point72 Capital Advisors Inc. is the general partner and Mr. Cohen controls both entities.
Century Therapeutics disclosure: RTW Investments, LP and Roderick Wong report shared beneficial ownership of 13,043,478 shares of Common Stock, representing 7.1% of the class. The percentages assume exercise of warrants to purchase 4,347,826 shares and are calculated using 179,722,750 shares outstanding as of February 28, 2026.
The filing states the RTW Funds have shared voting and shared dispositive power over the reported shares; the filing is made on behalf of the RTW Funds and Dr. Wong as managing partner.
Century Therapeutics reported first quarter 2026 results showing no collaboration revenue compared with $109,164k a year earlier, leading to a net loss. Operating expenses fell to $23,684k from $34,988k as research and development and general and administrative costs both declined.
The company posted a net loss of $21,645k, versus net income of $76,560k in the prior-year quarter, with basic and diluted net loss per share of $0.11 compared with earnings of $0.89. Cash and cash equivalents were $51,048k, and total assets rose to $326,553k with stockholders' equity of $264,744k.
Century Therapeutics, Inc. reported a net loss of $21.6 million for the three months ended March 31, 2026, compared with net income of $76.6 million a year earlier, when results included a large one-time collaboration revenue from Bristol-Myers Squibb.
Collaboration revenue was $0 this quarter versus $109.2 million in the prior-year period. Research and development expenses declined to $17.1 million from $26.6 million, and general and administrative expenses fell to $6.6 million from $8.4 million, reflecting cost controls and portfolio focus.
Cash, cash equivalents and investments totaled about $217.0 million, and management believes this will fund operations into the first quarter of 2029. During the quarter, the company closed a $126.4 million private placement, significantly increasing shares outstanding while supporting development of lead iPSC-derived cell therapy programs CNTY-813, CNTY-308 and CNTY-101.
Century Therapeutics, Inc. Senior Vice President of Finance & Operations Douglas Carr completed an automatic sale of 264 shares of common stock at $2.341 per share. The sale was made solely to cover tax withholding obligations arising from the vesting of restricted stock units and was not at his discretion.
Following this tax-related sale, Carr directly holds 506,997 shares of Century Therapeutics common stock, indicating that the transaction represents a very small portion of his overall equity position.
Century Therapeutics, Inc. is holding its 2026 annual stockholders meeting virtually on June 11, 2026 at 9:00 a.m. Eastern Time. Stockholders of record on April 16, 2026, when 180,354,197 common shares were outstanding, can vote online.
Key items include electing two Class II directors through 2029, ratifying Ernst & Young LLP as independent auditor for 2026, and approving an amendment to increase authorized common stock from 300,000,000 to 450,000,000 shares, plus a related adjournment proposal. The proxy also outlines board independence and committee structure, recent R&D milestones in cell therapies, a January 2026 securities purchase agreement with approximately $135 million in gross proceeds, and detailed 2025 executive and director compensation, including a $2.38 million total package for the CEO.
Century Therapeutics, Inc. is soliciting proxies for its virtual 2026 Annual Meeting to be held on June 11, 2026. Shareholders will vote on the election of two Class II directors, ratification of Ernst & Young LLP as auditor, and a proposed amendment to increase authorized common shares from 300,000,000 to 450,000,000. The meeting record date is April 16, 2026. Recent corporate highlights note IND-enabling progress across several cell therapy programs and a securities purchase that generated approximately $135 million in gross proceeds.